Bristol Reports Strong 2008 Earnings But Sharp Patent Cliffs Loom
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts question whether firm’s “string of pearls” growth strategy can offset patent hit.
You may also be interested in...
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
Bristol-Myers Squibb and Japanese partner Otsuka Pharmaceuticals have entered into a two-part deal that extends their 10-year-old collaboration to sell the blockbuster psychiatric drug Abilify (aripiprazole) in the U.S. and also gives Otsuka a presence in oncology in the U.S., Europe and Japan
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
The new deal enables BMS to smooth out its earnings in the face of a looming patent cliff and gives Otsuka an entrée into oncology.
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
The new deal enables BMS to smooth out its earnings in the face of a looming patent cliff and gives Otsuka an entrée into oncology.